Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Pens Gene Validation Deal with OGS

NEW YORK, Dec. 11 - Atugen of Berlin said Tuesday it had signed a deal to validate gene targets for Oxford GlycoSciences.

Under the terms of the deal, OGS of Oxford, UK, will provide targets to Atugen, which will validate them using its animal models.

Atugen has developed a technology called GeneBloc, which is designed to block protein production, enabling the company to determine gene function.

The deal marks Atugen's fifth collaboration deal this year. The company’s custormers include Astra Zeneca, Axys Pharmaceuticals, Bayer, Roche BioScience, and Boehringer Ingelheim.

Financial terms of the deal with OGS were not disclosed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.